To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.
Multiple Myeloma
DRUG: QL2109|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: DARZALEX FASPRO®
Percentage of Participants With Very Good Partial Response (VGPR) or Better, VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment., from baseline to week 24
Percentage of Participants With Very Good Partial Response (VGPR) or Better, VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment., from baseline to week 12 and week 48|Overall Response Rate, Overall response rate is defined as the percentage of randomized subjects who achieve a best response of PR or better using modified IMWG criteria as their best overall response, from baseline to week 24 and week 48|Overall survival at 18 months, the probability of being alive 18 months after randomization, from baseline to 18 months
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.